Brain Functional Magnetic Resonance Imaging Cue-reactivity Can Predict Baclofen Response in Alcohol Use Disorders.
10.9758/cpn.2018.16.3.290
- Author:
Bharath HOLLA
1
;
Sheshachala KARTHIK
;
Jitendriya BISWAL
;
Biju VISWANATH
;
Deepak JAYARAJAN
;
Rose Dawn BHARATH
;
Ganesan VENKATASUBRAMANIAN
;
Vivek BENEGAL
Author Information
1. Department of Psychiatry, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.
- Publication Type:Original Article
- Keywords:
Baclofen;
Functional magnetic resonance imaging;
Cue-reactivity;
Relapse prediction
- MeSH:
Baclofen*;
Brain*;
Cerebral Cortex;
Gyrus Cinguli;
Humans;
Inpatients;
Magnetic Resonance Imaging*;
Prospective Studies;
Recurrence;
Reward
- From:Clinical Psychopharmacology and Neuroscience
2018;16(3):290-301
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Baclofen is a promising treatment for alcohol use disorders (AUD), although its clinical response in humans is mixed. The present study aimed at investigating the impact of baclofen treatment on cue-induced brain activation pattern and its relationship with relapse outcomes. METHODS: Twenty-three inpatients with AUD underwent a functional magnetic resonance imaging cue-reactivity task before beginning medication with baclofen and 2 weeks later. Twelve additional inpatients with AUD, who did not receive any anticraving medications, formed the control group. All subjects were prospectively followed up for 90 days post-discharge or until lapse to first alcohol use. RESULTS: Whole-brain linear mixed effects analysis revealed a significant group-by-time interaction with greater activation of the bilateral dorsolateral pre-frontal cortex and right anterior cingulate cortex (ACC) following baclofen treatment in comparison with the control group. Further, cox regression analysis revealed that increased activation of ACC and deactivation of insular cortex (IC) was associated with longer time to first alcohol use only in the baclofen treatment group but not in the control group. CONCLUSION: This study provides preliminary evidence for the neural predictors of baclofen treatment response in AUD. Baclofen treatment in AUD was associated with changes in cue-reactivity at critical brain regions within the incentive-salience network. Importantly, baclofen treatment-related specific activation of regions involved in cognitive control (ACC) and deactivation of regions involved in reward anticipation (IC) prolonged the time to first alcohol drink.
